ReviewFrontiers in pharmacology2022
Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Green synthesis of silica nanoparticles using chia seeds boosts rice germination and physiological responses.Scientific reports · 2026Article
- MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson's Behavioral Dysfunction in Mice.International journal of nanomedicine · 2026Article
- Nanoparticle delivery systems for HIV pre-exposure prophylaxis (PrEP): advances and challenges.Beilstein journal of nanotechnology · 2026Review
- Multifunctional injectable GelMA hydrogel incorporating Icariin-loaded Mesoporous silica nanoparticles to promote osseointegration.iScience · 2025Article
- Nanotoxicity of Porous Silica Nanoparticles: Physicochemical Properties and Mechanistic Cellular Endpoints.Nanomaterials (Basel, Switzerland) · 2025Review
- Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management.Nanomedicine (London, England) · 2024Review
- Tuning the Physical State of Aripiprazole by Mesoporous Silica.Molecular pharmaceutics · 2024Article
- Article
- Advances of Antimicrobial Peptide-Based Biomaterials for the Treatment of Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Carbon dot incorporated mesoporous silica nanoparticles for targeted cancer therapy and fluorescence imaging.RSC advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supramolecular mesoporous silica nanoparticles (MSNs) offer distinct properties as opposed to micron-sized silica particles in terms of their crystal structure, morphology-porosity, toxicity, biological effects, and others. MSN biocompatibility has touched the pharmaceutical realm to exploit its robust synthesis pathway for delivery of various therapeutic molecules including macromolecules and small-molecule drugs. This article provides a brief review of MSN history followed by special emphasis on the influencing factors affecting morphology-porosity characteristics. Its applications as the next-generation drug delivery system (NGDDS) particularly in a controlled release dosage form via an oral drug delivery system are also presented and shall be highlighted as oral delivery is the most convenient route of drug administration with the economical cost of development through to scale-up for clinical trials and market launch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.